Vanguard Group Inc. Has $47.07 Million Holdings in Geron Corporation $GERN

Vanguard Group Inc. increased its stake in shares of Geron Corporation (NASDAQ:GERN) by 3.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 35,660,969 shares of the biopharmaceutical company’s stock after purchasing an additional 1,237,844 shares during the period. Vanguard Group Inc. owned approximately 5.59% of Geron worth $47,072,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. 55 North Private Wealth LLC acquired a new position in Geron in the fourth quarter valued at about $29,000. Swiss Life Asset Management Ltd grew its stake in Geron by 73.6% in the third quarter. Swiss Life Asset Management Ltd now owns 26,371 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 11,182 shares during the period. Fisher Asset Management LLC acquired a new position in Geron in the third quarter valued at about $37,000. Franklin Resources Inc. acquired a new position in Geron in the third quarter valued at about $45,000. Finally, Walleye Capital LLC acquired a new position in Geron in the second quarter valued at about $56,000. 73.71% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on GERN shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Geron in a research note on Monday, April 27th. TD Cowen reissued a “buy” rating on shares of Geron in a research note on Thursday, January 29th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $2.50.

Geron Stock Performance

Shares of Geron stock opened at $1.29 on Friday. The firm has a market cap of $827.56 million, a price-to-earnings ratio of -11.73 and a beta of 0.68. The stock’s 50-day moving average is $1.56 and its 200-day moving average is $1.44. Geron Corporation has a one year low of $1.04 and a one year high of $2.01. The company has a debt-to-equity ratio of 0.52, a current ratio of 6.78 and a quick ratio of 4.96.

Geron (NASDAQ:GERN) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. Geron had a negative return on equity of 23.31% and a negative net margin of 35.48%.The company had revenue of $51.84 million for the quarter, compared to analyst estimates of $50.59 million. Equities analysts predict that Geron Corporation will post -0.02 earnings per share for the current fiscal year.

About Geron

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.